Agilent's LSCA group, which houses the company's genomics and proteomics product lines, reported orders of $356 million for the first quarter of its 2005 fiscal year, up sharply from $307 million in orders for the year-ago quarter.
Life Science orders increased 18 percent, while Chemical Analysis orders increased by 15 percent, the company said.
The LSCA unit posted first-quarter revenues of $354 million, compared to $313 million in the first quarter of fiscal 2004.
Segment profits rose to $51 million, from $47 million in the prior-year period.
The LSCA unit's revenues made up 21 percent of Agilent's $1.66 billion in total revenues for the quarter, which rose only 1 percent over last year's first-quarter revenues.
Total orders for the company - including LSCA, Test and Measurement, Automated Test, and Semiconductor Products - dropped 7 percent year-over-year to $1.61 billion.
First-quarter net earnings were $103 million, or $.21 per diluted share, compared to $71 million, or $.14 per share, in the first quarter of 2004.
Agilent spent a total of $232 million on R&D during the quarter, up slightly from $229 million last year.
The company had $2.5 billion in cash and cash equivalents on hand as of Jan. 31.